.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01D_CytotoxicAntibioticsAndRelatedSubstances.L01DB11_Pixantrone.Pixantrone .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01D_CytotoxicAntibioticsAndRelatedSubstances.L01DB11_Pixantrone.Pixantrone| name: | Pixantrone | |
| ATC code: | L01DB11 | route: | intravenous |
| compartments: | 2 | |
| dosage: | 50 | mg |
| volume of distribution: | 31.4 | L |
| clearance: | 13.2 | L/h |
| other parameters in model implementation | ||
Pixantrone is an antineoplastic agent belonging to the class of aza-anthracenediones. It is structurally related to mitoxantrone and is used primarily for the treatment of relapsed or refractory aggressive non-Hodgkin B-cell lymphomas. Pixantrone has been granted conditional marketing authorization in the European Union but is not FDA-approved in the United States.
Pharmacokinetic parameters reported for adult cancer patients (mostly with non-Hodgkin lymphoma) receiving pixantrone as monotherapy, intravenous administration.